Intuitive Surgical Q1 results likely to be strong, says Cantor After Intuitive Surgical announced that its board has authorized an additional $1B share repurchase program and Massachusetts regulators called for increased scrutiny of robotic surgery, Cantor believes that Intuitive Surgical's risk/reward is still attractive. The firm reiterates a $575 price target and Buy rating.
Intuitive Surgical upgraded to Outperform from Market Perform at Leerink Leerink upgraded Intuitive Surgical to Outperform saying it has greater confidence in the company's ability to accelerate procedure growth after surveying surgeons. The firm raised its price target for shares to $560 from $450.
Intuitive Surgical rises, levels to watch At time of writing the shares were up over 3.9% to $493.83, well down from the session high at $505.74 which is resistance. At current price support is at the session low at $489.32, the opening price of the day. Goldman earlier upgraded the shares to a Buy, with a $584 price target.
Intuitive Surgical upgraded to Buy from Neutral at Goldman Goldman Sachs upgraded Intuitive Surgical (ISRG) to Buy citing an improving hospital spending environment and long-term uptake of surgery procedures in the U.S. The firm raised its price target for shares to $584 from $466. Shares of the robotic surgery maker closed Friday at $475.21.